Immunome (IMNM) Projected to Release Earnings on Thursday

Key Points

• Immunome is expected to report Q3 2026 results after market close on Thursday, November 5. Analysts forecast a loss of $0.6124 per share and revenue of approximately $0.15 million; the earnings call is scheduled for November 9.
• The company previously reported a larger-than-expected quarterly loss of $0.65 per share, compared with the $0.51 consensus estimate. Analysts project full-year and next-year losses of $2.48 and $2.76 per share, respectively.
• Immunome shares opened at $18.76, below their 50-day and 200-day moving averages, while analysts maintain a consensus “Moderate Buy” rating with a $34.25 price target. Insiders sold 223,368 shares worth $5.75 million over the past three months.

Immunome (NASDAQ:IMNM - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Immunome to post earnings of ($0.6124) per share and revenue of $0.15 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). On average, analysts expect Immunome to post ($2.48) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Immunome Trading Down 0.1%

NASDAQ IMNM opened at $18.76 on Thursday. The firm has a market capitalization of $2.13 billion, a P/E ratio of -7.42 and a beta of 2.55. The firm's fifty day moving average price is $22.87 and its two-hundred day moving average price is $22.49. Immunome has a 1 year low of $14.64 and a 1 year high of $30.06.

Wall Street Analyst Weigh In

IMNM has been the topic of several recent analyst reports. Wedbush restated an "outperform" rating and set a $35.00 price objective on shares of Immunome in a research note on Tuesday. Alliance Global Partners began coverage on shares of Immunome in a research note on Monday, September 21st. They issued a "buy" rating and a $32.00 target price for the company. William Blair started coverage on Immunome in a report on Friday, October 16th. They set an "outperform" rating for the company. Stifel Nicolaus assumed coverage on Immunome in a report on Wednesday, September 30th. They set a "hold" rating and a $24.00 price target for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Immunome in a research report on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $34.25.

Insiders Place Their Bets

In other news, insider Kinney Horn sold 90,616 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares in the company, valued at $1,263,682.94. The trade was a 64.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the sale, the director owned 92,211 shares of the company's stock, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 223,368 shares of company stock worth $5,747,142 over the last three months. Insiders own 7.21% of the company's stock.

Immunome Company Profile

Immunome, Inc NASDAQ: IMNM is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company's research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.